\-\ Texto\\:\\ \ \(0\)\
\-\ alert\\ and\\ oriented\\ x\\ 3\\.\\ left\\ homonymous\\ hemianopsia\\ with\\ macular\\ sparing\\,\\ horizontal\\ and\\ vertical\\ nystagmus\\,\\ normal\\ dtrs\\ bilat\\,\\ severe\\ upper\\ extremity\\ dysmetria\\ on\\ right\\,\\ abnormal\\ romberg\\.\\ unable\\ to\\ do\\ tandem\\ gait\\,\\ and\\ bumps\\ into\\ objects\\ on\\ left\\.\\ \\ lp\\:\\ positive\\ 14\\-3\\-3\\ protein\\,\\ increased\\ protein\\,\\ rbcs\\,\\ and\\ polysegs\\.\\ elevated\\ ast\\/alt\\.\\ elevated\\ thyroid\\ auto\\-antibodies\ \(0\)\
\-\ pt\\ was\\ admitted\\ to\\ the\\ neurology\\ ward\\,\\ and\\ a\\ full\\ neurological\\ work\\-up\\ was\\ started\\.\\ paraneoplastic\\/neoplastic\\ etiologies\\ were\\ excluded\\ due\\ to\\ rapid\\ progression\\ and\\ as\\ a\\ result\\ of\\ test\\ results\\.\\ pt\\â\\€\\™s\\ mental\\ status\\ continued\\ to\\ decline\\,\\ and\\ he\\ was\\ started\\ on\\ high\\ dose\\ steroids\\ course\\ for\\ possible\\ hashimoto\\â\\€\\™s\\ encephalopathy\\,\\ after\\ labs\\ showed\\ increased\\ auto\\-antibodies\\ to\\ the\\ thyroid\\.\\ transitioned\\ to\\ prednisone\\ 80mg\\ qd\\,\\ and\\ started\\ on\\ serroquel\\ and\\ geodon\\ for\\ agitation\\ and\\ sundowning\\.\\ \\ condition\\ continued\\ to\\ worsen\\ with\\ difficulty\\ protecting\\ airway\\ and\\ he\\ was\\ intubated\\ and\\ transferred\\ to\\ micu\\.\\ pt\\ was\\ placed\\ on\\ ventilator\\ and\\ found\\ to\\ have\\ a\\ retroperitoneal\\ bleed\\.\\ pt\\ had\\ brain\\ biopsy\\ that\\ confirmed\\ cjd\\.\\ after\\ consultation\\ with\\ the\\ family\\ he\\ was\\ extubated\\ and\\ moved\\ to\\ a\\ general\\ medicine\\ ward\\.\\ he\\ expired\\ the\\ following\\ week\\.\ \(0\)\
\-\ dwi\\ abnormalities\\ in\\ right\\ occipital\\ lobe\\/post\\ temporal\\ cortex\\ w\\/o\\ corresponding\\ t2\\ changes\\.\\ \\ \ \(0\)\
\-\ pet\\:\\ abnormal\\ hypometabolism\\ r\\ cerebrum\\ and\\ r\\ cerebellum\\.\ \(0\)\
\-\ creutzfeldt\\-jakob\\ disease\ \(0\)\
\-\ alzheimer\\ disease\\,\\ frontal\\ and\\ temporal\\ dementia\\,\\ hiv\\ and\\ hsv\\ encephalitis\\,\\ hydrocephalus\\,\\ metabolic\\ disorders\\,\\ multi\\-infarct\\ dementia\\,\\ diffuse\\ lewey\\ body\\ disease\\,\\ hashimoto\\ encephalopathy\\.\ \(0\)\
\-\ 63\\ y\\/o\\ male\\ with\\ history\\ of\\ nhl\\,\\ and\\ three\\ weeks\\ of\\ decreasing\\ visual\\ acuity\\,\\ gait\\ ataxia\\,\\ and\\ poor\\ coordination\\ of\\ left\\ arm\\,\\ that\\ is\\ worse\\ in\\ am\\ and\\ improving\\ during\\ the\\ course\\ of\\ day\\.\\ new\\ onset\\ of\\ personality\\ changes\\ and\\ mood\\ lability\\.\ \(0\)\
\-\ creutzfeldt\\-jacob\\ disease\\ \\(cjd\\)\\ is\\ a\\ transmissible\\ neurodegenerative\\ spongiform\\ encephalopathy\\,\\ that\\ is\\ progressive\\ and\\ ultimately\\ fatal\\,\\ with\\ no\\ effective\\ treatment\\ at\\ the\\ present\\ time\\.\\ it\\ is\\ classified\\ as\\ a\\ prion\\ disease\\,\\ which\\ is\\ an\\ abnormal\\ conformation\\ of\\ a\\ host\\ glycoprotein\\,\\ that\\ replicates\\ in\\ a\\ self\\-perpetuating\\ cycle\\ of\\ abnormal\\ proteins\\ and\\ amyloid\\ plaques\\.\\ cjd\\ has\\ a\\ long\\ incubation\\ period\\,\\ with\\ most\\ cases\\ presenting\\ in\\ the\\ sixth\\ or\\ seventh\\ decade\\ of\\ life\\.\\ cjd\\ has\\ a\\ mean\\ onset\\ of\\ 62\\ years\\,\\ with\\ reports\\ of\\ cases\\ ranging\\ from\\ 17\\ to\\ 83\\ years\\ of\\ age\\.\\ the\\ incidence\\ is\\ approximately\\ 1\\ case\\ per\\ million\\ internationally\\ and\\ in\\ the\\ united\\ states\\,\\ with\\ some\\ libyan\\ jewish\\ populations\\ and\\ a\\ few\\ populations\\ in\\ rural\\ areas\\ of\\ slovakia\\,\\ having\\ 60\\-100\\ times\\ this\\ rate\\ of\\ familial\\ cjd\\.\\ \ \(0\)\
\-\ there\\ are\\ three\\ classifications\\ of\\ cjd\\:\\ sporadic\\ \\(spontaneous\\ mutation\\)\\,\\ variant\\ \\(infectious\\)\\,\\ and\\ familial\\.\\ familial\\ cjd\\ accounts\\ for\\ about\\ 10\\%\\ of\\ all\\ cases\\,\\ and\\ is\\ inherited\\ in\\ an\\ autosomal\\ dominant\\ pattern\\.\\ \\ the\\ mean\\ duration\\ after\\ symptoms\\ present\\ is\\ 8\\ months\\ for\\ the\\ sporadic\\ form\\,\\ 16\\ months\\ for\\ variant\\,\\ and\\ 26\\ months\\ for\\ familial\\ form\\.\\ \ \(0\)\
\-\ cjd\\ is\\ characterized\\ by\\ a\\ rapidly\\ progressive\\ cognitive\\ imparement\\,\\ behavorial\\ abnormalities\\,\\ myoclonic\\ jerks\\,\\ higher\\ cortical\\ dysfunction\\ and\\ visual\\ cortical\\ abnormalities\\,\\ cerebellar\\ dysfunction\\,\\ and\\ pyramidal\\ and\\ extrapyramidal\\ signs\\.\\ these\\ signs\\ and\\ symptoms\\ steadily\\ increase\\,\\ with\\ death\\ primarily\\ occurring\\ secondary\\ to\\ bronchopneumonia\\,\\ due\\ to\\ overall\\ disability\\ and\\ a\\ bed\\-ridden\\ state\\.\ \(0\)\
\-\ testing\\ for\\ cjd\\ is\\ difficult\\ at\\ best\\,\\ and\\ in\\ its\\ early\\ stages\\ can\\ present\\ like\\ many\\ different\\ disease\\ processes\\,\\ with\\ a\\ definitive\\ diagnosis\\ being\\ accomplished\\ only\\ after\\ a\\ biopsy\\ of\\ brain\\ tissue\\.\\ sixty\\ percent\\ of\\ patients\\ show\\ characteristic\\ eeg\\ changes\\ of\\ periodic\\ sharp\\ wave\\ complexes\\ \\(pswcs\\)\\ on\\ a\\ slow\\ and\\ low\\-voltage\\ background\\.\\ \\ however\\,\\ eeg\\ has\\ a\\ low\\ specificity\\ and\\ a\\ sensitivity\\ of\\ only\\ 50\\.0\\%\\.\\ testing\\ for\\ brain\\ specific\\ proteins\\ such\\ as\\ the\\ 14\\-3\\-3\\ protein\\ and\\ the\\ neuron\\-specific\\ enolase\\ also\\ supports\\ a\\ diagnoses\\ of\\ cjd\\,\\ but\\ even\\ though\\ they\\ are\\ more\\ specific\\ than\\ eeg\\,\\ they\\ have\\ a\\ sensitivity\\ of\\ 84\\.0\\%\\ and\ \(0\)\
\-\ 73\\.3\\%\\ respectfully\\.\ \(1\)\
\-\ pet\\ scanning\\ may\\ show\\ regional\\ hypometabolism\\ of\\ glucose\\.\ \(0\)\
\-\ the\\ most\\ sensitive\\ test\\ to\\ date\\ is\\ the\\ mri\\ diffusion\\ weighted\\ images\\ \\(dwi\\)\\,\\ which\\ has\\ a\\ sensitivity\\ and\\ specificity\\ of\\ 92\\.3\\%\\ and\\ 93\\.8\\ respectfully\\.\\ dwi\\ is\\ more\\ sensitive\\ than\\ both\\ t2i\\ and\\ flair\\.\\ dwi\\ shows\\ symmetrical\\ high\\ intensity\\ lesions\\ in\\ the\\ striatum\\ \\(caudate\\ and\\ putamen\\)\\,\\ the\\ dorsomedial\\ thalamic\\ nuclei\\,\\ and\\ cerebral\\ cortical\\ lesions\\.\\ these\\ findings\\ were\\ identifiable\\ before\\ pswc\\â\\€\\™s\\ on\\ eeg\\ \\,\\ and\\ before\\ the\\ final\\ stages\\ of\\ the\\ disease\\,\\ which\\ results\\ in\\ brain\\ atrophy\\.\\ \\ \ \(0\)\
\-\ treatment\\ at\\ this\\ time\\ is\\ symptomatic\\ and\\ palliative\\,\\ but\\ a\\ number\\ of\\ experimental\\ interventions\\ are\\ being\\ tested\\,\\ such\\ as\\ antimalarial\\ quinacrine\\,\\ chlorpromazine\\,\\ and\\ pentosan\\ polysulphate\\,\\ which\\ prevent\\ prion\\ conversion\\ and\\ production\\,\\ and\\ an\\ immunization\\ that\\ reduces\\ the\\ cerebral\\ amyloid\\ accumulation\\.\\ \ \(0\)\
\-\ finally\\,\\ as\\ seen\\ with\\ this\\ patient\\,\\ cjd\\ must\\ always\\ be\\ in\\ a\\ differential\\ for\\ rapid\\ dementia\\ or\\ for\\ patients\\ experiencing\\ changes\\ in\\ mood\\,\\ ataxia\\,\\ and\\ visual\\ disturbances\\.\ \(0\)\
\-\ today\\,\\ we\\ can\\ only\\ ease\\ the\\ suffering\\ of\\ cjd\\,\\ but\\ on\\ the\\ horizon\\ a\\ treatment\\ may\\ be\\ near\\,\\ and\\ someday\\ we\\ can\\ offer\\ a\\ real\\ cure\\ and\\ a\\ way\\ to\\ stop\\ this\\ deadly\\ prion\\ disease\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cjd\\:\\ 0\\.4788281422768314\ \(0\)\
\-\ and\\:\\ 0\\.2923087853754626\ \(0\)\
\-\ of\\:\\ 0\\.1465570721332204\ \(0\)\
\-\ eeg\\:\\ 0\\.1326462547132402\ \(0\)\
\-\ prion\\:\\ 0\\.12715862164677671\ \(0\)\
\-\ the\\:\\ 0\\.12176051226270099\ \(0\)\
\-\ familial\\:\\ 0\\.12068102684136389\ \(0\)\
\-\ dwi\\:\\ 0\\.10544151333538176\ \(0\)\
\-\ to\\:\\ 0\\.10401353785739692\ \(0\)\
\-\ is\\:\\ 0\\.09874813112206357\ \(0\)\
\-\ dementia\\:\\ 0\\.09744593632975547\ \(0\)\
\-\ disease\\:\\ 0\\.0931445997665885\ \(0\)\
\-\ respectfully\\:\\ 0\\.08871551884092309\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.08765537780571427\ \(0\)\
\-\ sensitivity\\:\\ 0\\.08446528449518236\ \(0\)\
\-\ for\\:\\ 0\\.08406920735938163\ \(0\)\
\-\ in\\:\\ 0\\.08280126675158579\ \(0\)\
\-\ pt\\:\\ 0\\.079846028003726\ \(0\)\
\-\ protein\\:\\ 0\\.07722359179547776\ \(0\)\
\-\ hypometabolism\\:\\ 0\\.07653253419773261\ \(0\)\
\-\ mood\\:\\ 0\\.07653253419773261\ \(0\)\
\-\ proteins\\:\\ 0\\.0752339558180713\ \(0\)\
\-\ visual\\:\\ 0\\.07099521689433515\ \(0\)\
\-\ populations\\:\\ 0\\.07051244471615745\ \(0\)\
\-\ started\\:\\ 0\\.07009261946100656\ \(0\)\
\-\ brain\\:\\ 0\\.06916509256898827\ \(0\)\
\-\ hashimoto\\:\\ 0\\.06912080445830737\ \(0\)\
\-\ ward\\:\\ 0\\.06734774699859404\ \(0\)\
\-\ changes\\:\\ 0\\.06705273471671737\ \(0\)\
\-\ on\\:\\ 0\\.06701679066415739\ \(0\)\
\-\ abnormal\\:\\ 0\\.06665646055182968\ \(0\)\
\-\ he\\:\\ 0\\.06569972092168125\ \(0\)\
\-\ specificity\\:\\ 0\\.0634046425888554\ \(0\)\
\-\ specific\\:\\ 0\\.06305530611978953\ \(0\)\
\-\ sporadic\\:\\ 0\\.0630509711748808\ \(0\)\
\-\ amyloid\\:\\ 0\\.06270971187753466\ \(0\)\
\-\ mean\\:\\ 0\\.06116282489198243\ \(0\)\
\-\ abnormalities\\:\\ 0\\.06027615091578866\ \(0\)\
\-\ that\\:\\ 0\\.06018443922868013\ \(0\)\
\-\ with\\:\\ 0\\.059744112571773006\ \(0\)\
\-\ cortical\\:\\ 0\\.059740328677957096\ \(0\)\
\-\ stages\\:\\ 0\\.05934221285311665\ \(0\)\
\-\ was\\:\\ 0\\.058000052079135944\ \(0\)\
\-\ cases\\:\\ 0\\.05596842249011575\ \(0\)\
\-\ as\\:\\ 0\\.05571501061376712\ \(0\)\
\-\ sensitive\\:\\ 0\\.05456611849065074\ \(0\)\
\-\ ataxia\\:\\ 0\\.05386618397574224\ \(0\)\
\-\ dysfunction\\:\\ 0\\.05386618397574224\ \(0\)\
\-\ after\\:\\ 0\\.05382300668538244\ \(0\)\
\-\ we\\:\\ 0\\.05334038608499928\ \(0\)\
\-\ only\\:\\ 0\\.05198581489500859\ \(0\)\
\-\ rapid\\:\\ 0\\.051588678561541056\ \(0\)\
\-\ pet\\:\\ 0\\.05137725953815421\ \(0\)\
\-\ has\\:\\ 0\\.05067810847399931\ \(0\)\
\-\ which\\:\\ 0\\.05044945297802978\ \(0\)\
\-\ testing\\:\\ 0\\.0498334485899701\ \(0\)\
\-\ variant\\:\\ 0\\.04922814885468286\ \(0\)\
\-\ form\\:\\ 0\\.04850147043371771\ \(0\)\
\-\ months\\:\\ 0\\.048435815896787096\ \(0\)\
\-\ gait\\:\\ 0\\.04804553262154769\ \(0\)\
\-\ continued\\:\\ 0\\.04545417726552202\ \(0\)\
\-\ test\\:\\ 0\\.04511880292572809\ \(0\)\
\-\ before\\:\\ 0\\.04484789705011516\ \(0\)\
\-\ polysegs\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ serroquel\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ lewey\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ conformation\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ internationally\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ libyan\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ rural\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ slovakia\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ imparement\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ behavorial\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ extrapyramidal\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ pswcs\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ t2i\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ striatum\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ pswc\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ quinacrine\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ chlorpromazine\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ pentosan\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ polysulphate\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ someday\\:\\ 0\\.044357759420461544\ \(0\)\
\-\ can\\:\\ 0\\.04366675069273327\ \(0\)\
\-\ thyroid\\:\\ 0\\.043596185710841256\ \(0\)\
\-\ results\\:\\ 0\\.043227425244874\ \(0\)\
\-\ present\\:\\ 0\\.042698515121461576\ \(0\)\
\-\ temporal\\:\\ 0\\.04261394039324524\ \(0\)\
\-\ progressive\\:\\ 0\\.04248736734325697\ \(0\)\
\-\ geodon\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ sundowning\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ micu\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ lability\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ replicates\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ incubation\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ jerks\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ enolase\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ dorsomedial\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ antimalarial\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ horizon\\:\\ 0\\.042386207215592234\ \(0\)\
\-\ but\\:\\ 0\\.04114820891470462\ \(0\)\
\-\ protecting\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ transmissible\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ neurodegenerative\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ spongiform\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ glycoprotein\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ jewish\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ myoclonic\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ deadly\\:\\ 0\\.04098736866474859\ \(0\)\
\-\ course\\:\\ 0\\.040976299521802255\ \(0\)\
\-\ bronchopneumonia\\:\\ 0\\.03990234518973595\ \(0\)\
\-\ ease\\:\\ 0\\.03990234518973595\ \(0\)\
\-\ offer\\:\\ 0\\.03990234518973595\ \(0\)\
\-\ treatment\\:\\ 0\\.0396380452172116\ \(0\)\
\-\ they\\:\\ 0\\.039637433844696625\ \(0\)\
\-\ bumps\\:\\ 0\\.03901581645987928\ \(0\)\
\-\ 80mg\\:\\ 0\\.03901581645987928\ \(0\)\
\-\ million\\:\\ 0\\.03901581645987928\ \(0\)\
\-\ immunization\\:\\ 0\\.03901581645987928\ \(0\)\
\-\ reduces\\:\\ 0\\.03901581645987928\ \(0\)\
\-\ biopsy\\:\\ 0\\.03888552223086447\ \(0\)\
\-\ signs\\:\\ 0\\.03877043340767944\ \(0\)\
\-\ being\\:\\ 0\\.0386566906834734\ \(0\)\
\-\ cerebral\\:\\ 0\\.03843312010026703\ \(0\)\
\-\ nhl\\:\\ 0\\.038266267098866304\ \(0\)\
\-\ this\\:\\ 0\\.03812395260171536\ \(0\)\
\-\ elevated\\:\\ 0\\.03781758451255319\ \(0\)\
\-\ macular\\:\\ 0\\.03761697790903565\ \(0\)\
\-\ transitioned\\:\\ 0\\.03761697790903565\ \(0\)\
\-\ cerebrum\\:\\ 0\\.03761697790903565\ \(0\)\
\-\ experimental\\:\\ 0\\.03761697790903565\ \(0\)\
\-\ three\\:\\ 0\\.03723870078906264\ \(0\)\
\-\ dysmetria\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ agitation\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ alzheimer\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ classifications\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ steadily\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ sixty\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ complexes\\:\\ 0\\.037044264255009965\ \(0\)\
\-\ homonymous\\:\\ 0\\.036531954434023\ \(0\)\
\-\ bilat\\:\\ 0\\.036531954434023\ \(0\)\
\-\ extubated\\:\\ 0\\.036531954434023\ \(0\)\
\-\ tandem\\:\\ 0\\.036068513828698266\ \(0\)\
\-\ pyramidal\\:\\ 0\\.036068513828698266\ \(0\)\
\-\ such\\:\\ 0\\.035683911767054155\ \(0\)\
\-\ romberg\\:\\ 0\\.03564542570416633\ \(0\)\
\-\ personality\\:\\ 0\\.03564542570416633\ \(0\)\
\-\ host\\:\\ 0\\.03564542570416633\ \(0\)\
\-\ conversion\\:\\ 0\\.03564542570416633\ \(0\)\
\-\ onset\\:\\ 0\\.03562163903308497\ \(0\)\
\-\ objects\\:\\ 0\\.03525622235807872\ \(0\)\
\-\ suffering\\:\\ 0\\.03525622235807872\ \(0\)\
\-\ cure\\:\\ 0\\.03525622235807872\ \(0\)\
\-\ show\\:\\ 0\\.03521637655881321\ \(0\)\
\-\ dtrs\\:\\ 0\\.03489587634315335\ \(0\)\
\-\ worsen\\:\\ 0\\.03489587634315335\ \(0\)\
\-\ inherited\\:\\ 0\\.03489587634315335\ \(0\)\
\-\ moved\\:\\ 0\\.034560402229153686\ \(0\)\
\-\ putamen\\:\\ 0\\.034560402229153686\ \(0\)\
\-\ hsv\\:\\ 0\\.0342465871533227\ \(0\)\
\-\ seventh\\:\\ 0\\.0342465871533227\ \(0\)\
\-\ years\\:\\ 0\\.03400501752664032\ \(0\)\
\-\ ventilator\\:\\ 0\\.03395180320170417\ \(0\)\
\-\ lp\\:\\ 0\\.03341097455392554\ \(0\)\
\-\ rbcs\\:\\ 0\\.03341097455392554\ \(0\)\
\-\ coordination\\:\\ 0\\.03341097455392554\ \(0\)\
\-\ supports\\:\\ 0\\.03341097455392554\ \(0\)\
\-\ ranging\\:\\ 0\\.03316156367831005\ \(0\)\
\-\ thalamic\\:\\ 0\\.03316156367831005\ \(0\)\
\-\ time\\:\\ 0\\.0328810300133517\ \(0\)\
\-\ identifiable\\:\\ 0\\.032698123072985315\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.03248197877658515\ \(0\)\
\-\ expired\\:\\ 0\\.03248197877658515\ \(0\)\
\-\ improving\\:\\ 0\\.03248197877658515\ \(0\)\
\-\ fatal\\:\\ 0\\.03248197877658515\ \(0\)\
\-\ caudate\\:\\ 0\\.03248197877658515\ \(0\)\
\-\ decline\\:\\ 0\\.03227503494845338\ \(0\)\
\-\ wave\\:\\ 0\\.03227503494845338\ \(0\)\
\-\ interventions\\:\\ 0\\.03227503494845338\ \(0\)\
\-\ tested\\:\\ 0\\.03227503494845338\ \(0\)\
\-\ stop\\:\\ 0\\.03227503494845338\ \(0\)\
\-\ qd\\:\\ 0\\.03207654020329741\ \(0\)\
\-\ sixth\\:\\ 0\\.03207654020329741\ \(0\)\
\-\ cognitive\\:\\ 0\\.03207654020329741\ \(0\)\
\-\ due\\:\\ 0\\.03188768014770279\ \(0\)\
\-\ classified\\:\\ 0\\.03188583160236578\ \(0\)\
\-\ cycle\\:\\ 0\\.03188583160236578\ \(0\)\
\-\ disturbances\\:\\ 0\\.03188583160236578\ \(0\)\
\-\ today\\:\\ 0\\.03188583160236578\ \(0\)\
\-\ lesions\\:\\ 0\\.03185953282831846\ \(0\)\
\-\ low\\:\\ 0\\.03183146674229204\ \(0\)\
\-\ an\\:\\ 0\\.03181979219937554\ \(0\)\
\-\ are\\:\\ 0\\.031574973778410405\ \(0\)\
\-\ high\\:\\ 0\\.031527970303196845\ \(0\)\
\-\ than\\:\\ 0\\.03144681635192727\ \(0\)\
\-\ at\\:\\ 0\\.03143003097256765\ \(0\)\
\-\ symmetrical\\:\\ 0\\.03135485593876733\ \(0\)\
\-\ these\\:\\ 0\\.03132634126881043\ \(0\)\
\-\ patients\\:\\ 0\\.031207340424953052\ \(0\)\
\-\ decreasing\\:\\ 0\\.031190011473440735\ \(0\)\
\-\ mutation\\:\\ 0\\.031190011473440735\ \(0\)\
\-\ periodic\\:\\ 0\\.031190011473440735\ \(0\)\
\-\ background\\:\\ 0\\.031190011473440735\ \(0\)\
\-\ nystagmus\\:\\ 0\\.03087619639760975\ \(0\)\
\-\ acuity\\:\\ 0\\.03087619639760975\ \(0\)\
\-\ accounts\\:\\ 0\\.03087619639760975\ \(0\)\
\-\ regional\\:\\ 0\\.03087619639760975\ \(0\)\
\-\ disability\\:\\ 0\\.030581412445991215\ \(0\)\
\-\ nuclei\\:\\ 0\\.030581412445991215\ \(0\)\
\-\ more\\:\\ 0\\.030461336568447295\ \(0\)\
\-\ symptoms\\:\\ 0\\.030352406955974374\ \(0\)\
\-\ united\\:\\ 0\\.030303482743584072\ \(0\)\
\-\ experiencing\\:\\ 0\\.030303482743584072\ \(0\)\
\-\ scanning\\:\\ 0\\.030170256710340973\ \(0\)\
\-\ horizontal\\:\\ 0\\.03004058379821259\ \(0\)\
\-\ increased\\:\\ 0\\.029997875883032734\ \(0\)\
\-\ palliative\\:\\ 0\\.02991427939749646\ \(0\)\
\-\ finally\\:\\ 0\\.02991427939749646\ \(0\)\
\-\ production\\:\\ 0\\.0297911729225971\ \(0\)\
\-\ accomplished\\:\\ 0\\.029671106426558326\ \(0\)\
\-\ real\\:\\ 0\\.029671106426558326\ \(0\)\
\-\ neurology\\:\\ 0\\.029327732317272363\ \(0\)\
\-\ intubated\\:\\ 0\\.029327732317272363\ \(0\)\
\-\ diagnoses\\:\\ 0\\.029327732317272363\ \(0\)\
\-\ prednisone\\:\\ 0\\.02921845926857142\ \(0\)\
\-\ decade\\:\\ 0\\.02921845926857142\ \(0\)\
\-\ sparing\\:\\ 0\\.029111588020872204\ \(0\)\
\-\ vertical\\:\\ 0\\.029111588020872204\ \(0\)\
\-\ ultimately\\:\\ 0\\.029007015258693977\ \(0\)\
\-\ way\\:\\ 0\\.029007015258693977\ \(0\)\
\-\ most\\:\\ 0\\.02887051739090474\ \(0\)\
\-\ autosomal\\:\\ 0\\.0286098602411219\ \(0\)\
\-\ were\\:\\ 0\\.02859541042816636\ \(0\)\
\-\ bleed\\:\\ 0\\.02842282002665557\ \(0\)\
\-\ left\\:\\ 0\\.028385252067732982\ \(0\)\
\-\ effective\\:\\ 0\\.028331930538714755\ \(0\)\
\-\ 83\\:\\ 0\\.02815509483172745\ \(0\)\
\-\ consultation\\:\\ 0\\.02798446518305438\ \(0\)\
\-\ plaques\\:\\ 0\\.02798446518305438\ \(0\)\
\-\ occurring\\:\\ 0\\.02798446518305438\ \(0\)\
\-\ state\\:\\ 0\\.02798446518305438\ \(0\)\
\-\ may\\:\\ 0\\.02791642841857983\ \(0\)\
\-\ etiologies\\:\\ 0\\.027819620717727787\ \(0\)\
\-\ airway\\:\\ 0\\.027819620717727787\ \(0\)\
\-\ rapidly\\:\\ 0\\.027739247879090916\ \(0\)\
\-\ have\\:\\ 0\\.027712467057582256\ \(0\)\
\-\ encephalitis\\:\\ 0\\.02758238117770177\ \(0\)\
\-\ hiv\\:\\ 0\\.02743041737164018\ \(0\)\
\-\ percent\\:\\ 0\\.02743041737164018\ \(0\)\
\-\ excluded\\:\\ 0\\.02728305924532537\ \(0\)\
\-\ processes\\:\\ 0\\.02728305924532537\ \(0\)\
\-\ sharp\\:\\ 0\\.02728305924532537\ \(0\)\
\-\ death\\:\\ 0\\.027211021690278267\ \(0\)\
\-\ final\\:\\ 0\\.027211021690278267\ \(0\)\
\-\ transferred\\:\\ 0\\.02714003581600289\ \(0\)\
\-\ 63\\:\\ 0\\.02679986595462802\ \(0\)\
\-\ glucose\\:\\ 0\\.02679986595462802\ \(0\)\
\-\ accumulation\\:\\ 0\\.02679986595462802\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.02673459724271514\ \(0\)\
\-\ duration\\:\\ 0\\.02673459724271514\ \(0\)\
\-\ slow\\:\\ 0\\.02673459724271514\ \(0\)\
\-\ primarily\\:\\ 0\\.026606630751390067\ \(0\)\
\-\ 62\\:\\ 0\\.026420782166884153\ \(0\)\
\-\ atrophy\\:\\ 0\\.026241776209457283\ \(0\)\
\-\ am\\:\\ 0\\.026183542626858135\ \(0\)\
\-\ always\\:\\ 0\\.026183542626858135\ \(0\)\
\-\ corresponding\\:\\ 0\\.025957341561559415\ \(0\)\
\-\ dominant\\:\\ 0\\.025957341561559415\ \(0\)\
\-\ dose\\:\\ 0\\.025902398083984046\ \(0\)\
\-\ date\\:\\ 0\\.02563662450298103\ \(0\)\
\-\ alert\\:\\ 0\\.025534253437027487\ \(0\)\
\-\ number\\:\\ 0\\.025534253437027487\ \(0\)\
\-\ cerebellum\\:\\ 0\\.025483864944355825\ \(0\)\
\-\ characterized\\:\\ 0\\.025483864944355825\ \(0\)\
\-\ overall\\:\\ 0\\.025483864944355825\ \(0\)\
\-\ progression\\:\\ 0\\.025433993265845153\ \(0\)\
\-\ prevent\\:\\ 0\\.025433993265845153\ \(0\)\
\-\ different\\:\\ 0\\.025384627907533732\ \(0\)\
\-\ definitive\\:\\ 0\\.025335758691871504\ \(0\)\
\-\ higher\\:\\ 0\\.025192030611286415\ \(0\)\
\-\ metabolic\\:\\ 0\\.025145050090939876\ \(0\)\
\-\ oriented\\:\\ 0\\.02500677216526403\ \(0\)\
\-\ times\\:\\ 0\\.024961539783001807\ \(0\)\
\-\ disorders\\:\\ 0\\.024489920124395968\ \(0\)\
\-\ medicine\\:\\ 0\\.024449229962014835\ \(0\)\
\-\ steroids\\:\\ 0\\.024368857123377965\ \(0\)\
\-\ states\\:\\ 0\\.024368857123377965\ \(0\)\
\-\ period\\:\\ 0\\.024250735216858856\ \(0\)\
\-\ mental\\:\\ 0\\.024173551913284935\ \(0\)\
\-\ spontaneous\\:\\ 0\\.024135414886183853\ \(0\)\
\-\ though\\:\\ 0\\.024097574648293287\ \(0\)\
\-\ unable\\:\\ 0\\.024022766310773845\ \(0\)\
\-\ having\\:\\ 0\\.023912668489612425\ \(0\)\
\-\ incidence\\:\\ 0\\.02387651630798916\ \(0\)\
\-\ must\\:\\ 0\\.02376964506028994\ \(0\)\
\-\ occipital\\:\\ 0\\.023734536994201957\ \(0\)\
\-\ flair\\:\\ 0\\.023596586010602494\ \(0\)\
\-\ few\\:\\ 0\\.023529050952328785\ \(0\)\
\-\ poor\\:\\ 0\\.023396731330874897\ \(0\)\
\-\ diffusion\\:\\ 0\\.023364206487002187\ \(0\)\
\-\ difficulty\\:\\ 0\\.02333189775664445\ \(0\)\
\-\ even\\:\\ 0\\.02333189775664445\ \(0\)\
\-\ worse\\:\\ 0\\.023236239995677116\ \(0\)\
\-\ per\\:\\ 0\\.023020095699276953\ \(0\)\
\-\ difficult\\:\\ 0\\.023020095699276953\ \(0\)\
\-\ do\\:\\ 0\\.02298998757813249\ \(0\)\
\-\ neurological\\:\\ 0\\.022784294539982958\ \(0\)\
\-\ life\\:\\ 0\\.022755607459552667\ \(0\)\
\-\ admitted\\:\\ 0\\.02272708863276101\ \(0\)\
\-\ cerebellar\\:\\ 0\\.02269873609744965\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.022642522222472115\ \(0\)\
\-\ 17\\:\\ 0\\.022642522222472115\ \(0\)\
\-\ cortex\\:\\ 0\\.022586950805846464\ \(0\)\
\-\ near\\:\\ 0\\.022586950805846464\ \(0\)\
\-\ 26\\:\\ 0\\.022532007328271094\ \(0\)\
\-\ be\\:\\ 0\\.02250371498898287\ \(0\)\
\-\ characteristic\\:\\ 0\\.02242394852505758\ \(0\)\
\-\ infectious\\:\\ 0\\.022318239013364157\ \(0\)\
\-\ best\\:\\ 0\\.022318239013364157\ \(0\)\
\-\ general\\:\\ 0\\.02226623374726808\ \(0\)\
\-\ increase\\:\\ 0\\.02226623374726808\ \(0\)\
\-\ condition\\:\\ 0\\.022163862681314532\ \(0\)\
\-\ arm\\:\\ 0\\.022138603164618426\ \(0\)\
\-\ many\\:\\ 0\\.021869078729696\ \(0\)\
\-\ family\\:\\ 0\\.02182163985557346\ \(0\)\
\-\ presenting\\:\\ 0\\.021728128396132543\ \(0\)\
\-\ full\\:\\ 0\\.021682038515229676\ \(0\)\
\-\ placed\\:\\ 0\\.021613712622437\ \(0\)\
\-\ 16\\:\\ 0\\.021613712622437\ \(0\)\
\-\ reports\\:\\ 0\\.02156868965235117\ \(0\)\
\-\ symptomatic\\:\\ 0\\.021328250081917376\ \(0\)\
\-\ rate\\:\\ 0\\.02101843537326318\ \(0\)\
\-\ result\\:\\ 0\\.0207650241304709\ \(0\)\
\-\ about\\:\\ 0\\.0207650241304709\ \(0\)\
\-\ pattern\\:\\ 0\\.020708373633032774\ \(0\)\
\-\ weighted\\:\\ 0\\.020689635860214283\ \(0\)\
\-\ like\\:\\ 0\\.02061539860097715\ \(0\)\
\-\ its\\:\\ 0\\.020524168044328647\ \(0\)\
\-\ confirmed\\:\\ 0\\.020452396320188266\ \(0\)\
\-\ early\\:\\ 0\\.01999381573128924\ \(0\)\
\-\ extremity\\:\\ 0\\.01997763453156735\ \(0\)\
\-\ intensity\\:\\ 0\\.019695219591291103\ \(0\)\
\-\ status\\:\\ 0\\.019356697877048062\ \(0\)\
\-\ or\\:\\ 0\\.019298529080935625\ \(0\)\
\-\ labs\\:\\ 0\\.019216560050133516\ \(0\)\
\-\ new\\:\\ 0\\.019189010707151094\ \(0\)\
\-\ areas\\:\\ 0\\.018831608952702673\ \(0\)\
\-\ possible\\:\\ 0\\.018793471925601584\ \(0\)\
\-\ week\\:\\ 0\\.01865614083003858\ \(0\)\
\-\ showed\\:\\ 0\\.01847491068440683\ \(0\)\
\-\ long\\:\\ 0\\.018392594033619692\ \(0\)\
\-\ right\\:\\ 0\\.018392033281609904\ \(0\)\
\-\ positive\\:\\ 0\\.018277364801782717\ \(0\)\
\-\ body\\:\\ 0\\.01825464305002023\ \(0\)\
\-\ differential\\:\\ 0\\.018022263526419925\ \(0\)\
\-\ found\\:\\ 0\\.017947207742472653\ \(0\)\
\-\ frontal\\:\\ 0\\.0178523791373129\ \(0\)\
\-\ approximately\\:\\ 0\\.0176983288922452\ \(0\)\
\-\ day\\:\\ 0\\.01766809596979613\ \(0\)\
\-\ during\\:\\ 0\\.01756865598011682\ \(0\)\
\-\ severe\\:\\ 0\\.017558822921095188\ \(0\)\
\-\ some\\:\\ 0\\.01745195167339597\ \(0\)\
\-\ age\\:\\ 0\\.017413664498970402\ \(0\)\
\-\ diffuse\\:\\ 0\\.01739463337475795\ \(0\)\
\-\ following\\:\\ 0\\.016639660202776435\ \(0\)\
\-\ weeks\\:\\ 0\\.01662342497557629\ \(0\)\
\-\ all\\:\\ 0\\.016511271330802282\ \(0\)\
\-\ secondary\\:\\ 0\\.01644051500667585\ \(0\)\
\-\ however\\:\\ 0\\.016417156534073725\ \(0\)\
\-\ shows\\:\\ 0\\.016279314187851057\ \(0\)\
\-\ 10\\:\\ 0\\.016219283227480688\ \(0\)\
\-\ t2\\:\\ 0\\.01595795458602375\ \(0\)\
\-\ both\\:\\ 0\\.01546760355053916\ \(0\)\
\-\ upper\\:\\ 0\\.014822309469000894\ \(0\)\
\-\ into\\:\\ 0\\.014744597490233697\ \(0\)\
\-\ tissue\\:\\ 0\\.014550289664941835\ \(0\)\
\-\ diagnosis\\:\\ 0\\.014378747857257118\ \(0\)\
\-\ mri\\:\\ 0\\.014237797523693656\ \(0\)\
\-\ it\\:\\ 0\\.01419826522440387\ \(0\)\
\-\ case\\:\\ 0\\.013934848253566699\ \(0\)\
\-\ had\\:\\ 0\\.013819673611975884\ \(0\)\
\-\ findings\\:\\ 0\\.013689401677261757\ \(0\)\
\-\ seen\\:\\ 0\\.013058430988343745\ \(0\)\
\-\ also\\:\\ 0\\.013046765778360775\ \(0\)\
\-\ images\\:\\ 0\\.012830283776919735\ \(0\)\
\-\ male\\:\\ 0\\.012349651240795286\ \(0\)\
\-\ by\\:\\ 0\\.011778807398763087\ \(0\)\
\-\ normal\\:\\ 0\\.011324897000102179\ \(0\)\
\-\ there\\:\\ 0\\.011036530425723874\ \(0\)\
\-\ from\\:\\ 0\\.011016024560734722\ \(0\)\
\-\ history\\:\\ 0\\.010597201365893925\ \(0\)\
\-\ patient\\:\\ 0\\.009021506155069189\ \(0\)\
\-\ no\\:\\ 0\\.009019809262352919\ \(0\)\
